Molecular alterations and biomarkers in colorectal cancer

Toxicologic Pathology

Volumn 42, Issue 1, 2014, Pages 124-139

  Grady, William M ^a,b   Pritchard, Colin C ^b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

biomarkers; BRAF; cetuximab; chromosome instability; colon cancer; EGFR; KRAS; microsatellite instability; MSI; panitumumab.

Indexed keywords

APC PROTEIN; BETA CATENIN; CETUXIMAB; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; VASCULOTROPIN; WNT PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; COLON CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL POLYP; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; EPIGENETICS; GENE MUTATION; GENOMIC INSTABILITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

BIOMARKERS; BRAF; CETUXIMAB; CHROMOSOME INSTABILITY; COLON CANCER; EGFR; KRAS; MICROSATELLITE INSTABILITY; MSI; PANITUMUMAB.;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; HUMANS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84892715391     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623313505155     Document Type: Article

References (133)

1. Ahlquist D. A., Moertel C. G., McGill D. B. Screening for colorectal cancer. N Engl J Med. 1993 ; 329: 1351 1353-54
2. Ahlquist D. A., Sargent D. J., Loprinzi C. L., Levin T. R., Rex D. K., Ahnen D. J., Knigge K., Lance M. P., Burgart L. J., Hamilton S. R., Allison J. E., Lawson M. J., Devens M. E., Harrington J. J., Hillman S. L.. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008 ; 149: 441-50
3. Alazzouzi H., Alhopuro P., Salovaara R., Sammalkorpi H., Jarvinen H., Mecklin J.-P., Hemminki A., Schwartz S., Aaltonen L. A., Arango D.. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 2005 ; 11: 2606-11
4. Alexander J., Watanabe T., Wu T. T., Rashid A., Li S., Hamilton S. R.. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001 ; 158: 527-35
5. Alhopuro P., Alazzouzi H., Sammalkorpi H., Davalos V., Salovaara R., Hemminki A., Jarvinen H., Mecklin J. P., Schwartz S., Aaltonen L. A., Arango D.. SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res. 2005 ; 11: 6311-16
6. Allegra C. J., Jessup J. M., Somerfield M. R., Hamilton S. R., Hammond E. H., Hayes D. F., McAllister P. K., Morton R. F., Schilsky R. L.. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 ; 27: 2091-96
7. Amado R. G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D. J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S. D., Chang D. D.. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008 ; 26: 1626-34
8. Anastas J. N., Moon R. T.. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013 ; 13: 11-26
9. Artale S., Sartore-Bianchi A., Veronese S. M., Gambi V., Sarnataro C. S., Gambacorta M., Lauricella C., Siena S.. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008 ; 26: 4217-19
10. Bacher J. W., Flanagan L. A., Smalley R. L., Nassif N. A., Burgart L. J., Halberg R. B., Megid W. M., Thibodeau S. N.. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers. 2004 ; 20: 237-50
11. Baker K., Zhang Y., Jin C., Jass J. R.. Proximal versus distal hyperplastic polyps of the colorectum: Different lesions or a biological spectrum?. J Clin Pathol. 2004 ; 57: 1089-93
12. Barault L., Charon-Barra C., Jooste V., de la Vega M. F., Martin L., Roignot P., Rat P., Bouvier A. M., Laurent-Puig P., Faivre J., Chapusot C., Piard F.. Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases. Cancer Res. 2008 ; 68: 8541-46
13. Bardelli A., Parsons D. W., Silliman N., Ptak J., Szabo S., Saha S., Markowitz S., Willson J. K., Parmigiani G., Kinzler K. W., Vogelstein B., Velculescu V. E.. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003 ; 300: 949
14. Bardelli A., Siena S.. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010 ; 28: 1254-61
15. Baron J. A., Cole B. F., Sandler R. S., Haile R. W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R. W., Rothstein R., Burke C. A., Snover D. C., Church T. R., Allen J. I., Beach M., Beck G. J., Bond J. H., Byers T., Greenberg E. R., Mandel J. S., Marcon N., Mott L. A., Pearson L., Saibil F., van Stolk R. U.. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003 ; 348: 891-99
16. Baudhuin L. M., Burgart L. J., Leontovich O., Thibodeau S. N.. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer. 2005 ; 4: 255-65
17. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A.. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007 ; 67: 2643-48
18. Bertagnolli M. M., Niedzwiecki D., Compton C. C., Hahn H. P., Hall M., Damas B., Jewell S. D., Mayer R. J., Goldberg R. M., Saltz L. B., Warren R. S., Redston M.. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 ; 27: 1814-21
19. Bettstetter M., Dechant S., Ruemmele P., Grabowski M., Keller G., Holinski-Feder E., Hartmann A., Hofstaedter F., Dietmaier W.. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res. 2007 ; 13: 3221-28
20. Bittoni A., Faloppi L., Giampieri R., Cascinu S.. Selecting the best treatment for an individual patient. Recent Results Cancer Res. 2012 ; 196: 307-18
21. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J. T., Aparicio J., de Braud F., Donea S., Ludwig H., Schuch G., Stroh C., Loos A. H., Zubel A., Koralewski P.. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 ; 27: 663-71
22. Boland C., Thibodeau S., Hamilton S., Sidransky D., Eshlaman J., Burt R., Meltzer S., Ropdriguez B., M., Fode R., Ranzani G., Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 ; 58: 5248-57
23. Boulay J.-L., Mild G., Lowy A., Reuter J., Lagrange M., Terracciano L., Laffer U., Herrmann R., Rochlitz C.. SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J Cancer. 2002 ; 87: 630-34
24. Braun M. S., Richman S. D., Quirke P., Daly C., Adlard J. W., Elliott F., Barrett J. H., Selby P., Meade A. M., Stephens R. J., Parmar M. K., Seymour M. T.. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol. 2008 ; 26: 2690-98
25. Carethers J. M., Hawn M. T., Greenson J. K., Hitchcock C. L., Boland C. R.. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology. 1998 ; 114: 1188-95
26. Chittenden T. W., Howe E. A., Culhane A. C., Sultana R., Taylor J. M., Holmes C., Quackenbush J.. Functional classification analysis of somatically mutated genes in human breast and colorectal cancers. Genomics. 2008 ; 91: 508-11
27. Chung D.. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis. Gastroenterology. 2000 ; 119: 854-65
28. Ciardiello F., Tortora G.. EGFR antagonists in cancer treatment. N Engl J Med. 2008 ; 358: 1160-74
29. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E.. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 ; 351: 337-45
30. Danielsen S. A., Lind G. E., Bjornslett M., Meling G. I., Rognum T. O., Heim S., Lothe R. A.. Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation- status. Hum Mutat. 2008 ; 29: E252-62
31. Deacu E., Mori Y., Sato F., Yin J., Olaru A., Sterian A., Xu Y., Wang S., Schulmann K., Berki A., Kan T., Abraham J. M., Meltzer S. J.. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Cancer Res. 2004 ; 64: 7690-96
32. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M. P., Bastit L., Killian A., Sesboue R., Tuech J. J., Queuniet A. M., Paillot B., Sabourin J. C., Michot F., Michel P., Frebourg T.. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer. 2007 ; 96: 1166-69
33. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A.. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008 ; 26: 5705-12
34. Domingo E., Laiho P., Ollikainen M., Pinto M., Wang L., French A. J., Westra J., Frebourg T., Espin E., Armengol M., Hamelin R., Yamamoto H., Hofstra R. M., Seruca R., Lindblom A., Peltomaki P., Thibodeau S. N., Aaltonen L. A., Schwartz S.. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004 ; 41: 664-68
35. Douillard J., Siena S., Cassidy J. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): The PRIME trial. Eur J Cancer. 2009 ; 7 (suppl; abstr 10LBA). S6
36. Downward J.. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003 ; 3: 11-22
37. Eppert K., Scherer S., Ozcelik H., Pirone R., Hoodless P., Kim H., Tsui L.-C., Bapat B., Gallinger S., Andrulis I., Thomsen G., Wrana J., Attisano L.. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal cancer. Cell. 1996 ; 86: 543-52
38. European Medicines Agency. (2008). Committee for Medicinal Products for Human Use May 2008 Plenary Meeting monthly report. http://www.emea.europa.eu/ pdfs/human/press/pr/27923508en.pdf. Accessed date: 10-12-2013.
39. Ezzeldin H. H., Diasio R. B.. Predicting fluorouracil toxicity: Can we finally do it?. J Clin Oncol. 2008 ; 26: 2080-82
40. Fallik D., Borrini F., Boige V., Viguier J., Jacob S., Miquel C., Sabourin J. C., Ducreux M., Praz F.. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003 ; 63: 5738-44
41. French A. J., Sargent D. J., Burgart L. J., Foster N. R., Kabat B. F., Goldberg R., Shepherd L., Windschitl H. E., Thibodeau S. N.. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008 ; 14: 3408-15
42. Fuchs C., Ogino S., Meyerhardt J. A. KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2009 ; 27: A - 4037
43. Goldstein N. S.. Serrated pathway and APC (conventional)-type colorectal polyps: Molecular-morphologic correlations, genetic pathways, and implications for classification. Am J Clin Pathol. 2006 ; 125: 146-53
44. Grady W., Myeroff L., Swinler S., Rajput A., Thiagalingam S., Lutterbaugh J., Neumann A., Brattain M., Chang J., Kim S.-J., Kinzler K., Vogelstein B., Willson J., Markowitz S.. Mutational inactivation of transforming growth factor ß recepor type II in microsatellite stable colon cancers. Cancer Res. 1999 ; 59: 320-24
45. Grady W., Rajput A., Myeroff L., Liu D., Willis J., Kwon K., Markowitz S.. Mutation of the type II TGF-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 1998 ; 58: 3101-4
46. Grady W. M.. Genomic instability and colon cancer. Cancer Metastasis Rev. 2004 ; 23: 11-27
47. Grady W. M., Carethers J. M.. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008 ; 135: 1079-99
48. Grady W. M., Markowitz S The TGF-β family. Derynck R. Miyazano K., ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press ; 2008: 889-938.
49. Hampel H., Frankel W. L., Martin E., Arnold M., Khanduja K., Kuebler P., Nakagawa H., Sotamaa K., Prior T. W., Westman J., Panescu J., Fix D., Lockman J., Comeras I., de la Chapelle A.. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005 ; 352: 1851-60
50. Hanahan D., Weinberg R. A.. The hallmarks of cancer. Cell. 2000 ; 100: 57-70
51. Hanahan D., Weinberg R. A. Hallmarks of cancer: The next generation. Cell. 2011 ; 144: 646-74
52. Hermsen M., Postma C., Baak J., Weiss M., Rapallo A., Sciutto A., Roemen G., Arends J. W., Williams R., Giaretti W., De Goeij A., Meijer G. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology. 2002 ; 123: 1109-19
53. Hinoue T., Weisenberger D. J., Pan F., Campan M., Kim M., Young J., Whitehall V. L., Leggett B. A., Laird P. W.. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One. 2009 ; 4: e8357
54. Hoskins J. M., Goldberg R. M., Qu P., Ibrahim J. G., McLeod H. L.. UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst. 2007 ; 99: 1290-95
55. Iacopetta B., Kawakami K., Watanabe T.. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: Is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?. Int J Clin Oncol. 2008 ; 13: 498-503
56. Itzkowitz S., Brand R., Jandorf L., Durkee K., Millholland J., Rabeneck L., Schroy P. C., 3rd Sontag, S., Johnson D., Markowitz S., Paszat L., Berger B. M. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008 ; 103: 2862-70
57. Itzkowitz S. H., Jandorf L., Brand R., Rabeneck L., Schroy P. C., 3rd Sontag, S., Johnson D., Skoletsky J., Durkee K., Markowitz S., Shuber A. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007 ; 5: 111-17
58. Jacobs B., De Roock W., Piessevaux H., Van Oirbeek R., Biesmans B., De Schutter J., Fieuws S., Vandesompele J., Peeters M., Van Laethem J. L., Humblet Y., Penault-Llorca F., De Hertogh G., Laurent-Puig P., Van Cutsem E., Tejpar S.. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009 ; 27: 5068-74
59. Jass J. R.. Hyperplastic polyps and colorectal cancer: Is there a link?. Clin Gastroenterol Hepatol. 2004 ; 2: 1-8
60. Jhawer M., Goel S., Wilson A. J., Montagna C., Ling Y. H., Byun D. S., Nasser S., Arango D., Shin J., Klampfer L., Augenlicht L. H., Perez-Soler R., Mariadason J. M.. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008 ; 68: 1953-61
61. Jo W. S., Carethers J. M.. Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark. 2006 ; 2: 51-60
62. Kane M., Loda M., Gaida G., Lipman J., Mishra R., Goldman H., Jessup J. M., Kolodner R.. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997 ; 57: 808-11
63. Karapetis C. S., Khambata-Ford S., Jonker D. J., O'Callaghan C. J., Tu D., Tebbutt N. C., Simes R. J., Chalchal H., Shapiro J. D., Robitaille S., Price T. J., Shepherd L., Au H. J., Langer C., Moore M. J., Zalcberg J. R.. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 ; 359: 1757-65
64. Kim G. P., Colangelo L. H., Wieand H. S., Paik S., Kirsch I. R., Wolmark N., Allegra C. J.. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2007 ; 25: 767-72
65. Laurent-Puig P., Cayre A., Manceau G., Buc E., Bachet J. B., Lecomte T., Rougier P., Lievre A., Landi B., Boige V., Ducreux M., Ychou M., Bibeau F., Bouche O., Reid J., Stone S., Penault-Llorca F.. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009 ; 27: 5924-30
66. Li M., Chen W. D., Papadopoulos N., Goodman S. N., Bjerregaard N. C., Laurberg S., Levin B., Juhl H., Arber N., Moinova H., Durkee K., Schmidt K., He Y., Diehl F., Velculescu V. E., Zhou S., Diaz L. A., Kinzler K. W., Markowitz S. D., Vogelstein B.. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009 ; 27: 858-63
67. Liang J. T., Huang K. C., Lai H. S., Lee P. H., Cheng Y. M., Hsu H. C., Cheng A. L., Hsu C. H., Yeh K. H., Wang S. M., Tang C., Chang K. J.. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer. 2002 ; 101: 519-25
68. Liao X., Morikawa T., Lochhead P., Imamura Y., Kuchiba A., Yamauchi M., Nosho K., Qian Z. R., Nishihara R., Meyerhardt J. A., Fuchs C. S., Ogino S.. Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin Cancer Res. 2012 ; 18: 2257-68
69. Lievre A., Bachet J. B., Le Corre D., Boige V., Landi B., Emile J. F., Cote J. F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., Laurent-Puig P.. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006 ; 66: 3992-95
70. Lievre A., Blons H., Laurent-Puig P.. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene. 2010 ; 29: 3033-43
71. Little M. P., Vineis P., Li G.. A stochastic carcinogenesis model incorporating multiple types of genomic instability fitted to colon cancer data. J Theor Biol. 2008 ; 254: 229-38
72. Loupakis F., Ruzzo A., Cremolini C., Vincenzi B., Salvatore L., Santini D., Masi G., Stasi I., Canestrari E., Rulli E., Floriani I., Bencardino K., Galluccio N., Catalano V., Tonini G., Magnani M., Fontanini G., Basolo F., Falcone A., Graziano F.. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009 ; 101: 715-21
73. Lubomierski N., Plotz G., Wormek M., Engels K., Kriener S., Trojan J., Jungling B., Zeuzem S., Raedle J.. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer. 2005 ; 104: 952-61
74. Maley C. C., Galipeau P. C., Finley J. C., Wongsurawat V. J., Li X., Sanchez C. A., Paulson T. G., Blount P. L., Risques R. A., Rabinovitch P. S., Reid B. J.. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006 ; 38: 468-73
75. Mao M., Tian F., Mariadason J. M., Tsao C. C., Lemos R., Dayyani F., Gopal Y. N., Jiang Z. Q., Wistuba II, Tang X. M., Bornman W. G., Bollag G., Mills G. B., Powis G., Desai J., Gallick G. E., Davies M. A., Kopetz S.. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2012 ; 19: 657-67
76. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R., Zborowska E., Kinzler K., Vogelstein B., Brattain M., Willson J. K. V.. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 1995 ; 268: 1336-38
77. Matsuzaki K., Deng G., Tanaka H., Kakar S., Miura S., Kim Y. S.. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res. 2005 ; 11: 8564-69
78. Meyerhardt J. A., Mayer R. J.. Systemic therapy for colorectal cancer. N Engl J Med. 2005 ; 352: 476-87
79. Miyaki M., Iijima T., Kimura J., Yasuno M., Mori T., Hayashi Y., Koike M., Shitara N., Iwama T., Kuroki T.. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res. 1999 ; 59: 4506-9
80. NCCN (National Comprehensive Cancer Network). (2010). Clinical Practice Guidelines in Oncology: Colon Cancer V.2.2010. http://www.nccn.org/ professionals/physician-gls/PDF/colon.pdf. Accessed date: 10-12-2013.
81. Noffsinger A. E.. Serrated polyps and colorectal cancer: New pathway to malignancy. Ann Rev Pathol. 2009 ; 4: 343-64
82. Nosho K., Irahara N., Shima K., Kure S., Kirkner G. J., Schernhammer E. S., Hazra A., Hunter D. J., Quackenbush J., Spiegelman D., Giovannucci E. L., Fuchs C. S., Ogino S.. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE. 2008 ; 3: e3698
83. Ogino S., Nosho K., Kirkner G. J., Kawasaki T., Meyerhardt J. A., Loda M., Giovannucci E. L., Fuchs C. S.. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009 ; 58: 90-96
84. Ogino S., Nosho K., Kirkner G. J., Shima K., Irahara N., Kure S., Chan A. T., Engelman J. A., Kraft P., Cantley L. C., Giovannucci E. L., Fuchs C. S.. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009 ; 27: 1477-84
85. Osborn N. K., Ahlquist D. A.. Stool screening for colorectal cancer: Molecular approaches. Gastroenterology. 2005 ; 128: 192-206
86. Palomaki G. E., Bradley L. A., Douglas M. P., Kolor K., Dotson W. D.. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med. 2009 ; 11: 21-34
87. Parsons D. W., Wang T. L., Samuels Y., Bardelli A., Cummins J. M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J. K., Markowitz S., Kinzler K. W., Vogelstein B., Lengauer C., Velculescu V. E.. Colorectal cancer: Mutations in a signalling pathway. Nature. 2005 ; 436: 792
88. Popat S., Hubner R., Houlston R. S.. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005 ; 23: 609-18
89. Prenen H., De Schutter J., Jacobs B., De Roock W., Biesmans B., Claes B., Lambrechts D., Van Cutsem E., Tejpar S.. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009 ; 15: 3184-88
90. Pritchard C. C., Grady W. M.. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011 ; 60: 116-29
91. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K. W., Vogelstein B., Velculescu V. E.. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002 ; 418: 934
92. Razis E., Briasoulis E., Vrettou E., Skarlos D. V., Papamichael D., Kostopoulos I., Samantas E., Xanthakis I., Bobos M., Galanidi E., Bai M., Gikonti I., Koukouma A., Kafiri G., Papakostas P., Kalogeras K. T., Kosmidis P., Fountzilas G.. Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study. BMC Cancer. 2008 ; 8: 234
93. Ribic C. M., Sargent D. J., Moore M. J., Thibodeau S. N., French A. J., Goldberg R. M., Hamilton S. R., Laurent-Puig P., Gryfe R., Shepherd L. E., Tu D., Redston M., Gallinger S.. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003 ; 349: 247-57
94. Richman S. D., Seymour M. T., Chambers P., Elliott F., Daly C. L., Meade A. M., Taylor G., Barrett J. H., Quirke P.. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin Oncol. 2009 ; 27: 5931-37
95. Rodriguez J., Frigola J., Vendrell E., Risques R. A., Fraga M. F., Morales C., Moreno V., Esteller M., Capella G., Ribas M., Peinado M. A.. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 2006 ; 66: 8462-9468
96. Roth A. D., Tejpar S., Delorenzi M., Yan P., Fiocca R., Klingbiel D., Dietrich D., Biesmans B., Bodoky G., Barone C., Aranda E., Nordlinger B., Cisar L., Labianca R., Cunningham D., Van Cutsem E., Bosman F.. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010 ; 28: 466-74
97. Saltz L. B., Meropol N. J., Loehrer P. J., Needle M. N., Kopit J., Mayer R. J.. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004 ; 22: 1201-8
98. Saltz L. B., Niedzwiecki D., Hollis D., Goldberg R. M., Hantel A., Thomas J. P., Fields A. L., Mayer R. J.. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol. 2007 ; 25: 3456-61
99. Samowitz W. S., Powers M. D., Spirio L. N., Nollet F., van Roy F., Slattery M. L.. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 1999 ; 59: 1442-44
100. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S. M., Riggins G. J., Willson J. K. V., Markowitz S., Kinzler K. W., Vogelstein B., Velculescu V. E.. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004 ; 304: 554
101. Sargent D., Marsoni S., Thibodeau S. N., Labianca R., Hamilton S. R., Torri V., Monges G., Ribic C., Grothey A., Gallinger S.. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol. 2008 4008 ; 26 :
102. Sartore-Bianchi A., Di Nicolantonio F., Nichelatti M., Molinari F., De Dosso S., Saletti P., Martini M., Cipani T., Marrapese G., Mazzucchelli L., Lamba S., Veronese S., Frattini M., Bardelli A., Siena S.. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009a ; 4: e7287
103. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., Di Nicolantonio F., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A.. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009b ; 69: 1851-57
104. Schwab M., Zanger U. M., Marx C., Schaeffeler E., Klein K., Dippon J., Kerb R., Blievernicht J., Fischer J., Hofmann U., Bokemeyer C., Eichelbaum M.. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol. 2008 ; 26: 2131-38
105. Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., Hernandez N. S., Chen X., Ahmed S., Konishi K., Hamilton S. R., Issa J. P.. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007 ; 104: 18654-59
106. Shia J.. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008 ; 10: 293-300
107. Shia J., Klimstra D. S., Bagci P., Basturk O., Adsay N. V.. TNM staging of colorectal carcinoma: Issues and caveats. Semin Diagn Pathol. 2012 ; 29: 142-53
108. Shia J., Klimstra D. S., Li A. R., Qin J., Saltz L., Teruya-Feldstein J., Akram M., Chung K. Y., Yao D., Paty P. B., Gerald W., Chen B.. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 2005 ; 18: 1350-56
109. Siena S., Sartore-Bianchi A., Di Nicolantonio F., Balfour J., Bardelli A.. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009 ; 101: 1308-24
110. Sinicrope F. A., Shi Q.. Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: Are we ready yet?. J Natl Cancer Inst. 2012 ; 104: 1616-18
111. Smith R. A., Cokkinides V., Brooks D., Saslow D., Brawley O. W.. Cancer screening in the United States, 2010: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2013 ; 60: 99-119
112. South C. D., Yearsley M., Martin E., Arnold M., Frankel W., Hampel H.. Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genet Med. 2009 ; 11: 812-17
113. Takaku K., Oshima M., Miyoshi H., Matsui M., Seldin M. F., Taketo M. M.. Intestinal tumorigenesis in compound mutant mice of both Dpc4(Smad4) and Apc genes. Cell. 1998 ; 92: 645-56
114. Tanaka T., Watanabe T., Kazama Y., Tanaka J., Kanazawa T., Kazama S., Nagawa H.. Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancer - a study matched for tumor depth and pathology. J Surg Oncol. 2008 ; 97: 69-73
115. Tejpar S., Bertagnolli M., Bosman F., Lenz H. J., Garraway L., Waldman F., Warren R., Bild A., Collins-Brennan D., Hahn H., Harkin D. P., Kennedy R., Ilyas M., Morreau H., Proutski V., Swanton C., Tomlinson I., Delorenzi M., Fiocca R., Van Cutsem E., Roth A.. Prognostic and predictive biomarkers in resected colon cancer: Current status and future perspectives for integrating genomics into biomarker discovery. Oncologist. 2010 ; 15: 390-404
116. Tol J., Nagtegaal I. D., Punt C. J.. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009 ; 361: 98-99
117. Van Cutsem E., Kohne C. H., Hitre E., Zaluski J., Chang Chien C. R., Makhson A., D'Haens G., Pinter T., Lim R., Bodoky G., Roh J. K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P.. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 ; 360: 1408-17
118. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J. L., Van Laethem J. L., Maurel J., Richardson G., Wolf M., Amado R. G.. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007 ; 25: 1658-64
119. Vogelstein B., Fearon E., Hamilton S., Kern S., Presinger A., Leppert M., Nakamura Y., White R., Smits A., Bos J.. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 ; 319: 525-32
120. Wagle N., Emery C., Berger M. F., Davis M. J., Sawyer A., Pochanard P., Kehoe S. M., Johannessen C. M., Macconaill L. E., Hahn W. C., Meyerson M., Garraway L. A.. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 ; 29: 3085-96
121. Walther A., Houlston R., Tomlinson I.. Association between chromosomal instability and prognosis in colorectal cancer: A meta-analysis. Gut. 2008 ; 57: 941-50
122. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D.. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009 ; 9: 489-99
123. Wang L., Cunningham J. M., Winters J. L., Guenther J. C., French A. J, Boardman L. A., Burgart L. J., McDonnell S. K., Schaid D. J., Thibodeau S. N. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 2003 ; 63: 5209-12
124. Watanabe T., Wu T.-T., Catalano P. J., Ueki T., Satriano R., Haller D. G., Benson A. B., Hamilton S. R.. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001 ; 344: 1196-206
125. Weisenberger D. J., Siegmund K. D., Campan M., Young J., Long T. I., Faasse M. A., Kang G. H., Widschwendter M., Weener D., Buchanan D., Koh H., Simms L., Barker M., Leggett B., Levine J., Kim M., French A. J., Thibodeau S. N., Jass J., Haile R., Laird P. W.. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006 ; 38: 787-93
126. Yokota T.. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?. Anticancer Agents Med Chem. 2012 ; 12: 163-71
127. Yu M., Grady W. M.. Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: Novel targeted therapies and advances in the treatment of colorectal cancer. Therap Adv Gastroenterol. 2012 ; 5: 319-37
128. Yu M., Trobridge P., Wang Y., Kanngurn S., Morris S. M., Knoblaugh S., Grady W. M. Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene. 2013 ;:
129. Yuan T. L., Cantley L. C.. PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 2008 ; 27: 5497-510
130. Zauber P., Sabbath-Solitare M., Marotta S. P., Bishop D. T.. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003 ; 56: 137-40
131. Zhang L.. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. 2008 ; 10: 301-7
132. Zlobec I., Kovac M., Erzberger P., Molinari F., Bihl M. P., Rufle A., Foerster A., Frattini M., Terracciano L., Heinimann K., Lugli A.. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer. 2010 ; 127: 2569-75
133. Zou H., Taylor W. R., Harrington J. J., Hussain F. T., Cao X., Loprinzi C. L., Levine T. R., Rex D. K., Ahnen D., Knigge K. L., Lance P., Jiang X., Smith D. I., Ahlquist D. A.. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 2009 ; 136: 459-70